Medivir AB announces that the company’s patent application, covering both substance claims for fostroxacitabine bralpamide and its use for liver cancer treatment, has recently been approved by the Chinese patent authority.
Medivir’s patent application for fostrox approved in China Read More »
Allgenesis Biotherapeutics Inc. announced topline data from the company’s Phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor agonist formulated as an aqueous solution eye drop for the treatment of Dry Eye Disease.
Telix Pharmaceuticals Limited announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- -targeting PET/CT[1] imaging agent TLX250-CDx, exploring this potential target across a broad range of cancer indications.
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland.
IASO Biotechnology announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its IASO-782 Injection for use in U.S. clinical trials for Autoimmune hematological disorders, including primary immune thrombocytopenia and warm autoimmune hemolytic anemia.
Seres Therapeutics, Inc. and Nestlé Health Science announced the presentation of a post-hoc analysis from the Phase 3 development program for VOWST™, the first and only U.S. Food and Drug Administration -approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI.
Bristol Myers Squibb announced the first disclosure of primary analysis results from two pivotal studies, TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi in patients with relapsed or refractory follicular lymphoma and the relapsed or refractory mantle cell lymphoma cohort of TRANSCEND NHL 001, an open-label, multicenter, Phase 1, single-arm, seamless-design
The Bespoke Gene Therapy Consortium intends to bring AAV-based gene therapies to patients whose diseases are often ignored by commercial interests.
Public-Private Alliance Chooses Eight Rare Diseases for Focused Gene Therapy Development Read More »
Jubilant Therapeutics’s differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.
Scott Rivers, president and managing partner of an executive search and talent branding firm, weighs in on what managers can do to keep top talent.
Opinion: Manage a Team? Here’s How to Keep Your Top Performers Read More »
